This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
The tumor microenvironment (TME) promotes tumor development via complex intercellular signaling, aiding tumor growth and suppressing immunity. Eph receptors (Eph) and their ephrin ligands control cell interactions during normal development, and reemerge in tumors and the TME, where they are implicated in invasion, metastasis, and angiogenesis. Recent studies also indicate roles for Ephs in suppressing immune responses by controlling tumor interactions with innate and adaptive immune cells within the TME. Accordingly, inhibiting these functions can promote immune response and efficacy of immune checkpoint inhibition. This research highlights Ephs as potential targets to enhance efficacy of immune-based therapies in patients with cancer.
Footnotes
Cancer Res 2021;81:801–5
- Received September 8, 2020.
- Revision received October 8, 2020.
- Accepted November 6, 2020.
- Published first November 11, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
Volume 81, Issue 4
